0 75

Cited 0 times in

Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial

Authors
 Jee Suk Chang  ;  Sang Wun Kim  ;  Yeon-Joo Kim  ;  Joo-Young Kim  ;  Sang-Yoon Park  ;  Jin Hee Kim  ;  Tae-Kyu Jang  ;  Yong Bae Kim 
Citation
 Gynecologic Oncology, Vol.151(1) : 39-45, 2018 
Journal Title
 Gynecologic Oncology 
ISSN
 0090-8258 
Issue Date
2018
Keywords
Ovarian cancer ; Radiation therapy ; Recurrent
Abstract
OBJECTIVE: To evaluate the efficacy and safety of involved-field radiation therapy (IFRT) in patients with locoregionally confined recurrent or persistent epithelial ovarian cancer. METHODS: This study included patients with recurrent epithelial ovarian cancer eligible for IFRT either during diagnosis of the recurrence or after salvage therapies. IFRT was performed at a dose of ≥45 Gy for all tumors with 10-15-mm margins as seen on standard imaging. The primary endpoint was progression-free survival (PFS); the secondary endpoints were safety, response rate, local control, and overall survival (OS). RESULTS: Thirty patients with a mean number of 5.7 metastatic lesions each were enrolled between 2014 and 2016. Seventeen were treated with 3-D conformal radiation therapy (RT) and 13 with intensity-modulated RT. IFRT was well tolerated in all patients, and acute toxicity ≥ grade 2 was not observed. One case of grade 3 abdominal pain was reported 10 months post-RT. The overall and complete response rates were 85.7% and 50%, respectively. After a median follow-up of 28 (range, 17-42) months, the median PFS was 7 months. The 2-year PFS rate was 39.3%. Six of the 16 patients who developed outfield disease progression after IFRT were successfully treated with repeat IFRT as salvage treatment. The 3-year local control and OS rates were 84.4% and 55.8%, respectively. CONCLUSIONS: Although the primary endpoint was not met, IFRT might be safe and effective for in-field tumor control in patients with persistent epithelial ovarian cancer with a limited number of metastatic foci. We plan to conduct a larger scale multi-center phase II prospective study.
Full Text
https://www.sciencedirect.com/science/article/pii/S0090825818311296
DOI
10.1016/j.ygyno.2018.08.012
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
Yonsei Authors
김상운(Kim, Sang Wun) ORCID logo https://orcid.org/0000-0002-8342-8701
김용배(Kim, Yong Bae) ORCID logo https://orcid.org/0000-0001-7573-6862
장지석(Chang, Jee Suk Paul) ORCID logo https://orcid.org/0000-0001-7685-3382
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165091
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse